Ainos, Inc. announced that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors. This represents an improvement from the previously reported 80% accuracy. The data was collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for statistical evaluation.
This milestone validates AI Nose as a deployable solution for non-contact hygiene monitoring in long-term care (LTC) settings. The improved accuracy accelerates the platform's commercial rollout, addressing critical gaps in elder care. Ainos is positioned to lead the emerging SmellTech category with this validated technology.
The enhanced accuracy underscores the effectiveness and reliability of the AI Nose in a sensitive healthcare application. This achievement is crucial for building confidence in the technology and driving its adoption in the elderly care market. It demonstrates the continuous improvement and commercial readiness of the AI Nose platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.